Suppr超能文献

升级治疗用于接受吸入皮质类固醇治疗但哮喘控制不佳的儿童。

Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.

机构信息

University of Wisconsin School of Medicine and Public Health, Madison, USA.

出版信息

N Engl J Med. 2010 Mar 18;362(11):975-85. doi: 10.1056/NEJMoa1001278. Epub 2010 Mar 2.

Abstract

BACKGROUND

For children who have uncontrolled asthma despite the use of low-dose inhaled corticosteroids (ICS), evidence to guide step-up therapy is lacking.

METHODS

We randomly assigned 182 children (6 to 17 years of age), who had uncontrolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinded step-up therapies in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up). We used a triple-crossover design and a composite of three outcomes (exacerbations, asthma-control days, and the forced expiratory volume in 1 second) to determine whether the frequency of a differential response to the step-up regimens was more than 25%.

RESULTS

A differential response occurred in 161 of 165 patients who were evaluated (P<0.001). The response to LABA step-up therapy was most likely to be the best response, as compared with responses to LTRA step-up (relative probability, 1.6; 95% confidence interval [CI], 1.1 to 2.3; P=0.004) and ICS step-up (relative probability, 1.7; 95% CI, 1.2 to 2.4; P=0.002). Higher scores on the Asthma Control Test before randomization (indicating better control at baseline) predicted a better response to LABA step-up (P=0.009). White race predicted a better response to LABA step-up, whereas black patients were least likely to have a best response to LTRA step-up (P=0.005).

CONCLUSIONS

Nearly all the children had a differential response to each step-up therapy. LABA step-up was significantly more likely to provide the best response than either ICS or LTRA step-up. However, many children had a best response to ICS or LTRA step-up therapy, highlighting the need to regularly monitor and appropriately adjust each child's asthma therapy. (ClinicalTrials.gov number, NCT00395304.)

摘要

背景

对于尽管使用低剂量吸入皮质激素(ICS)但哮喘仍未得到控制的儿童,缺乏指导升级治疗的证据。

方法

我们随机分配了 182 名年龄在 6 至 17 岁之间的儿童(每天两次接受 100 微克氟替卡松),他们在接受每天两次 100 微克氟替卡松治疗的同时接受了三种盲法升级治疗,顺序随机进行,为期 16 周:每天两次 250 微克氟替卡松(ICS 升级)、每天两次 100 微克氟替卡松加 50 微克长效β-激动剂(LABA 升级)或每天两次 100 微克氟替卡松加 5 或 10 毫克白三烯受体拮抗剂(LTRA 升级)。我们使用三交叉设计和三个结果(加重、哮喘控制天数和 1 秒用力呼气量)的组合来确定对升级方案的差异反应频率是否超过 25%。

结果

在 165 名接受评估的患者中,有 161 名(P<0.001)出现了差异反应。与 LTRA 升级(相对概率,1.6;95%置信区间[CI],1.1 至 2.3;P=0.004)和 ICS 升级(相对概率,1.7;95%CI,1.2 至 2.4;P=0.002)相比,LABA 升级治疗的反应最有可能是最佳反应。在随机分组前的哮喘控制测试中获得较高的分数(表明在基线时控制较好)预示着对 LABA 升级治疗的反应更好(P=0.009)。白种人预测对 LABA 升级的反应更好,而黑人患者对 LTRA 升级的反应最差(P=0.005)。

结论

几乎所有儿童对每种升级治疗都有差异反应。与 ICS 或 LTRA 升级相比,LABA 升级更有可能提供最佳反应。然而,许多儿童对 ICS 或 LTRA 升级治疗有最佳反应,这突出表明需要定期监测并适当调整每个儿童的哮喘治疗。(临床试验.gov 编号,NCT00395304。)

相似文献

1
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
N Engl J Med. 2010 Mar 18;362(11):975-85. doi: 10.1056/NEJMoa1001278. Epub 2010 Mar 2.
2
Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.
J Allergy Clin Immunol. 2014 Feb;133(2):350-6. doi: 10.1016/j.jaci.2013.07.039. Epub 2013 Sep 29.
5
Randomized comparison of strategies for reducing treatment in mild persistent asthma.
N Engl J Med. 2007 May 17;356(20):2027-39. doi: 10.1056/NEJMoa070013.
8
Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.
Br J Clin Pharmacol. 2003 Nov;56(5):494-500. doi: 10.1046/j.1365-2125.2003.01887.x.

引用本文的文献

1
Level of agreement between two asthma control questionnaires in children and adolescents.
J Bras Pneumol. 2025 Jun 13;51(2):e20240407. doi: 10.36416/1806-3756/e20240407. eCollection 2025.
4
Tailored Adherence Incentives for Childhood Asthma Medications: A Randomized Clinical Trial.
JAMA Pediatr. 2025 May 1;179(5):500-507. doi: 10.1001/jamapediatrics.2025.0010.
5
Health system characteristics and evidence-based asthma care.
Front Allergy. 2025 Feb 24;6:1528526. doi: 10.3389/falgy.2025.1528526. eCollection 2025.
6
Evaluating Severe Therapy-Resistant Asthma in Children: Diagnostic and Therapeutic Strategies.
Medicina (Kaunas). 2024 Nov 2;60(11):1799. doi: 10.3390/medicina60111799.
7
Dangers of under-treatment and over-treatment with inhaled corticosteroids in children with asthma.
Pediatr Pulmonol. 2025 Jan;60(1):e27327. doi: 10.1002/ppul.27327. Epub 2024 Nov 8.
9
Comparison of Asthma Phenotypes in Severe Asthma Cohorts (SARP, U-BIOPRED, ProAR and COREA) From 4 Continents.
Allergy Asthma Immunol Res. 2024 Jul;16(4):338-352. doi: 10.4168/aair.2024.16.4.338.
10
Objectives for algorithmic decision-making systems in childhood asthma: Perspectives of children, parents, and physicians.
Digit Health. 2024 Feb 21;10:20552076241227285. doi: 10.1177/20552076241227285. eCollection 2024 Jan-Dec.

本文引用的文献

2
The minimally important difference of the Asthma Control Test.
J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1. doi: 10.1016/j.jaci.2009.06.053. Epub 2009 Sep 19.
3
Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children.
Cochrane Database Syst Rev. 2009 Jul 8(3):CD007949. doi: 10.1002/14651858.CD007949.
5
Genetic ancestry modifies pharmacogenetic gene-gene interaction for asthma.
Pharmacogenet Genomics. 2009 Jul;19(7):489-96. doi: 10.1097/FPC.0b013e32832c440e.
6
Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values.
N Engl J Med. 2009 Apr 16;360(16):1592-5. doi: 10.1056/NEJMp0810561.
7
Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children.
Pediatr Allergy Immunol. 2009 Dec;20(8):763-71. doi: 10.1111/j.1399-3038.2009.00861.x. Epub 2009 Feb 20.
8
Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma.
J Allergy Clin Immunol. 2009 Feb;123(2):411-6. doi: 10.1016/j.jaci.2008.11.016. Epub 2009 Jan 3.
9
Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients.
Ann Allergy Asthma Immunol. 2008 Jun;100(6):551-7. doi: 10.1016/S1081-1206(10)60055-5.
10
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007.
J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. doi: 10.1016/j.jaci.2007.09.043.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验